Atalanta Therapeutics
PrivateLast Round
Series B
Jan 28, 2025
Total Funding Raised
$207M
Company Overview
Atalanta Therapeutics is a biotechnology company that develops RNA interference therapeutics aimed at treating neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atalanta Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Atalanta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 28, 2025 | ||||
| Series A | Jan 11, 2021 |
Key People
Founding team and executive leadership
Atalanta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series B |
| EQT Ventures | Series B |
| Mirae Asset | Series B |
| abrdn Inc. | Series B |
| F-Prime Capital | Series B, Series A |
| Genentech | Series A |
| GHR Foundation | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2025
Alicia Secor stepped down as Chief Executive Officer.
- Jun 18, 2025
Joanne Kotz appointed as new Chief Executive Officer.
Atalanta Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Atalanta Therapeutics's valuation, stock price, and market status.